Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | CCR9 | P51686 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21543416 | 0.98 | DGAT1 (0.41) | DGAT1HSP90AA1CCR9EGFRCYP19A1 | |
| SCHEMBL2602384 | 0.74 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL1106088 | 0.74 | DGAT1 (0.35) | DGAT1CYP19A1 | |
| SCHEMBL31505123 | 0.73 | HPGD (0.34) | DGAT1 | |
| SCHEMBL803486 | 0.73 | DGAT1 (0.34) | DGAT1CYP19A1 | |
| SCHEMBL8183467 | 0.73 | HPGD (0.34) | DGAT1 | |
| SCHEMBL21719169 | 0.73 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL11092586 | 0.73 | CYP19A1 (0.35) | DGAT1CYP19A1 | |
| SCHEMBL31505058 | 0.73 | DGAT1 (0.34) | DGAT1CCR9 | |
| SCHEMBL22907602 | 0.70 | SIRT3 (0.42) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | DGAT1 3761/4885HSP90AA1 1289/4885CCR9 3753/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | DGAT1 3761/4885HSP90AA1 1289/4885CCR9 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.